Email Updates

You are here

CAB-LA is a Highly Effective HIV Prevention Option; Now what?

December 17, 2020

Px Pulse Logo

This episode of Px Pulse explores an exciting new option for HIV prevention—long-acting injectable cabotegravir (CAB-LA). In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Overall HIV incidence rates in the trials were remarkably low, demonstrating that both oral and injectable PrEP are safe and effective options.

Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?

In this episode, Raphael Landovitz and Sinead Delany-Moretlwe, lead investigators of the HPTN 083 and 084 trials, respectively, lay out the topline research findings and discuss how CAB-LA fits in with existing HIV prevention options.

And with an eye on translating research into implementation and impact, Definate Nhamo, a program manager from Pangaea Zimbabwe AIDS Trust (PZAT), and Jason Reed, a technical advisor with Jhpiego, outline priorities for the work ahead in policy making, programming and funding to get CAB-LA to those who need it, as part of an expanding toolbox for HIV prevention.